Abstract
Digital Twin (DT) technology, introduced by Michael Grieves in 2002, creates dynamic virtual models of patients by integrating data from electronic health records, medical imaging, wearable sensors, genomics, and real-time physiological monitoring. Using artificial intelligence, machine learning, physics-based modeling, and big data analytics, DTs simulate disease progression, predict treatment responses, and support clinical decision-making. In healthcare, they enable personalized medicine, remote patient monitoring, and improved treatment planning for conditions such as cardiovascular diseases, cancer, orthopedic disorders, and type 1 diabetes. In drug development, DTs support clinical trial design, enable in-silico trials, and reduce costs and recruitment challenges. However, issues like data privacy, validation, ethical concerns, technological limitations, and regulatory uncertainty remain challenges. Overall, digital twin technology has strong potential to advance predictive, preventive, and personalized healthcare.